Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies.

Arruga F, Vaisitti T, Deaglio S.

Front Oncol. 2018 Nov 26;8:550. doi: 10.3389/fonc.2018.00550. eCollection 2018. Review.

2.

Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.

Vaisitti T, Braggio E, Allan JN, Arruga F, Serra S, Zamò A, Tam W, Chadburn A, Furman RR, Deaglio S.

Cancer Res. 2018 Jul 1;78(13):3413-3420. doi: 10.1158/0008-5472.CAN-17-4004. Epub 2018 May 7.

PMID:
29735551
3.

Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?

Vaisitti T, Arruga F, Deaglio S.

Int J Mol Sci. 2018 Apr 12;19(4). pii: E1167. doi: 10.3390/ijms19041167. Review.

4.

Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.

Audrito V, Managò A, La Vecchia S, Zamporlini F, Vitale N, Baroni G, Cignetto S, Serra S, Bologna C, Stingi A, Arruga F, Vaisitti T, Massi D, Mandalà M, Raffaelli N, Deaglio S.

J Natl Cancer Inst. 2018 Mar 1;110(3). doi: 10.1093/jnci/djx198.

PMID:
29309612
5.

Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia.

Maffei R, Fiorcari S, Vaisitti T, Martinelli S, Benatti S, Debbia G, Rossi D, Zucchini P, Potenza L, Luppi M, Gaidano G, Deaglio S, Marasca R.

Oncotarget. 2017 Sep 27;8(52):90013-90027. doi: 10.18632/oncotarget.21341. eCollection 2017 Oct 27.

6.

Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor.

Vaisitti T, Gaudino F, Ouk S, Moscvin M, Vitale N, Serra S, Arruga F, Zakrzewski JL, Liou HC, Allan JN, Furman RR, Deaglio S.

Haematologica. 2017 Nov;102(11):1878-1889. doi: 10.3324/haematol.2017.173419. Epub 2017 Aug 31.

7.

Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22.

Arruga F, Gizdic B, Bologna C, Cignetto S, Buonincontri R, Serra S, Vaisitti T, Gizzi K, Vitale N, Garaffo G, Mereu E, Diop F, Neri F, Incarnato D, Coscia M, Allan J, Piva R, Oliviero S, Furman RR, Rossi D, Gaidano G, Deaglio S.

Leukemia. 2017 Sep;31(9):1882-1893. doi: 10.1038/leu.2016.383. Epub 2016 Dec 26.

PMID:
28017968
8.

Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment.

Serra S, Vaisitti T, Audrito V, Bologna C, Buonincontri R, Chen SS, Arruga F, Brusa D, Coscia M, Jaksic O, Inghirami G, Rossi D, Furman RR, Robson SC, Gaidano G, Chiorazzi N, Deaglio S.

Blood Adv. 2016 Nov 22;1(1):47-61. doi: 10.1182/bloodadvances.2016000984. eCollection 2016 Nov 29.

9.

SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.

Bologna C, Buonincontri R, Serra S, Vaisitti T, Audrito V, Brusa D, Pagnani A, Coscia M, D'Arena G, Mereu E, Piva R, Furman RR, Rossi D, Gaidano G, Terhorst C, Deaglio S.

J Clin Invest. 2016 Jan;126(1):181-94. doi: 10.1172/JCI83013. Epub 2015 Nov 30.

10.

Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia.

Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, Coscia M, Maffei R, Rossi D, Wang T, Inghirami G, Rizzi M, Gaidano G, Garcia JG, Wolberger C, Raffaelli N, Deaglio S.

Blood. 2015 Jan 1;125(1):111-23. doi: 10.1182/blood-2014-07-589069. Epub 2014 Nov 3.

11.

The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting.

Vaisitti T, Audrito V, Serra S, Buonincontri R, Sociali G, Mannino E, Pagnani A, Zucchetto A, Tissino E, Vitale C, Coscia M, Usai C, Pepper C, Gattei V, Bruzzone S, Deaglio S.

Leukemia. 2015 Feb;29(2):356-68. doi: 10.1038/leu.2014.207. Epub 2014 Jul 3.

PMID:
24990614
12.

Multiple metamorphoses of CD38 from prognostic marker to disease modifier to therapeutic target in chronic lymphocytic leukemia.

Vaisitti T, Audrito V, Serra S, Bologna C, Arruga F, Brusa D, Buonincontri R, Gizdic B, Deaglio S.

Curr Top Med Chem. 2013;13(23):2955-64. Review.

PMID:
24171772
13.

Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia.

Arruga F, Gizdic B, Serra S, Vaisitti T, Ciardullo C, Coscia M, Laurenti L, D'Arena G, Jaksic O, Inghirami G, Rossi D, Gaidano G, Deaglio S.

Leukemia. 2014 May;28(5):1060-70. doi: 10.1038/leu.2013.319. Epub 2013 Oct 30.

PMID:
24170027
14.

CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells.

Vaisitti T, Serra S, Pepper C, Rossi D, Laurenti L, Gaidano G, Malavasi F, Deaglio S.

Leukemia. 2013 Apr;27(5):1177-81. doi: 10.1038/leu.2012.260. Epub 2012 Sep 7. No abstract available.

PMID:
22955446
15.

Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options.

Audrito V, Vaisitti T, Serra S, Bologna C, Brusa D, Malavasi F, Deaglio S.

Cancer Lett. 2013 Jan 1;328(1):27-35. doi: 10.1016/j.canlet.2012.08.012. Epub 2012 Aug 19. Review.

PMID:
22910767
16.

The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.

Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G.

J Exp Med. 2012 Aug 27;209(9):1537-51. doi: 10.1084/jem.20120904. Epub 2012 Aug 13.

17.

Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.

Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, Chiaretti S, Del Giudice I, Fabbri G, Bruscaggin A, Spina V, Deambrogi C, Marinelli M, Famà R, Greco M, Daniele G, Forconi F, Gattei V, Bertoni F, Deaglio S, Pasqualucci L, Guarini A, Dalla-Favera R, Foà R, Gaidano G.

Blood. 2012 Mar 22;119(12):2854-62. doi: 10.1182/blood-2011-12-395673. Epub 2012 Feb 3.

18.

The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells.

Zucchetto A, Vaisitti T, Benedetti D, Tissino E, Bertagnolo V, Rossi D, Bomben R, Dal Bo M, Del Principe MI, Gorgone A, Pozzato G, Gaidano G, Del Poeta G, Malavasi F, Deaglio S, Gattei V.

Leukemia. 2012 Jun;26(6):1301-12. doi: 10.1038/leu.2011.369. Epub 2012 Jan 6.

PMID:
22289918
19.

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.

Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, Fangazio M, Vaisitti T, Monti S, Chiaretti S, Guarini A, Del Giudice I, Cerri M, Cresta S, Deambrogi C, Gargiulo E, Gattei V, Forconi F, Bertoni F, Deaglio S, Rabadan R, Pasqualucci L, Foà R, Dalla-Favera R, Gaidano G.

Blood. 2011 Dec 22;118(26):6904-8. doi: 10.1182/blood-2011-08-373159. Epub 2011 Oct 28.

20.

CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death.

Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, Laurenti L, D'Arena G, Coscia M, Tripodo C, Inghirami G, Robson SC, Gaidano G, Malavasi F, Deaglio S.

Blood. 2011 Dec 1;118(23):6141-52. doi: 10.1182/blood-2011-08-374728. Epub 2011 Oct 13.

21.

Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma.

Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, Spina V, Bruscaggin A, Monti S, Cerri M, Cresta S, Fangazio M, Arcaini L, Lucioni M, Marasca R, Thieblemont C, Capello D, Facchetti F, Kwee I, Pileri SA, Foà R, Bertoni F, Dalla-Favera R, Pasqualucci L, Gaidano G.

Blood. 2011 Nov 3;118(18):4930-4. doi: 10.1182/blood-2011-06-359166. Epub 2011 Aug 31.

22.

Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network.

Audrito V, Vaisitti T, Rossi D, Gottardi D, D'Arena G, Laurenti L, Gaidano G, Malavasi F, Deaglio S.

Cancer Res. 2011 Jul 1;71(13):4473-83. doi: 10.1158/0008-5472.CAN-10-4452. Epub 2011 May 12.

23.

CD38 in chronic lymphocytic leukemia: from bench to bedside?

Deaglio S, Vaisitti T, Serra S, Audrito V, Bologna C, D'Arena G, Laurenti L, Gottardi D, Malavasi F.

Mini Rev Med Chem. 2011 Jun;11(6):503-7.

PMID:
21561406
24.

NAD+-metabolizing ecto-enzymes shape tumor-host interactions: the chronic lymphocytic leukemia model.

Vaisitti T, Audrito V, Serra S, Bologna C, Brusa D, Malavasi F, Deaglio S.

FEBS Lett. 2011 Jun 6;585(11):1514-20. doi: 10.1016/j.febslet.2011.04.036. Epub 2011 Apr 19. Review.

25.

E2A is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemia.

Saborit-Villarroya I, Vaisitti T, Rossi D, D'Arena G, Gaidano G, Malavasi F, Deaglio S.

Leukemia. 2011 Mar;25(3):479-88. doi: 10.1038/leu.2010.291. Epub 2011 Jan 7.

PMID:
21212793
26.

A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome.

Rasi S, Spina V, Bruscaggin A, Vaisitti T, Tripodo C, Forconi F, De Paoli L, Fangazio M, Sozzi E, Cencini E, Laurenti L, Marasca R, Visco C, Xu-Monette ZY, Gattei V, Young KH, Malavasi F, Deaglio S, Gaidano G, Rossi D.

Br J Haematol. 2011 Feb;152(3):284-94. doi: 10.1111/j.1365-2141.2010.08482.x. Epub 2010 Dec 1.

PMID:
21121903
27.

CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells.

Deaglio S, Vaisitti T, Zucchetto A, Gattei V, Malavasi F.

Semin Cancer Biol. 2010 Dec;20(6):416-23. doi: 10.1016/j.semcancer.2010.08.003. Epub 2010 Sep 9. Review.

PMID:
20817095
28.

CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells.

Vaisitti T, Aydin S, Rossi D, Cottino F, Bergui L, D'Arena G, Bonello L, Horenstein AL, Brennan P, Pepper C, Gaidano G, Malavasi F, Deaglio S.

Leukemia. 2010 May;24(5):958-69. doi: 10.1038/leu.2010.36. Epub 2010 Mar 11.

PMID:
20220774
29.

CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells.

Deaglio S, Aydin S, Grand MM, Vaisitti T, Bergui L, D'Arena G, Chiorino G, Malavasi F.

Mol Med. 2010 Mar;16(3-4):87-91. doi: 10.2119/molmed.2009.00146. Epub 2009 Nov 20.

30.

Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology.

Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, Vaisitti T, Aydin S.

Physiol Rev. 2008 Jul;88(3):841-86. doi: 10.1152/physrev.00035.2007. Review.

31.

CD38 at the junction between prognostic marker and therapeutic target.

Deaglio S, Aydin S, Vaisitti T, Bergui L, Malavasi F.

Trends Mol Med. 2008 May;14(5):210-8. doi: 10.1016/j.molmed.2008.02.005. Epub 2008 Apr 9. Review.

PMID:
18403265
32.

CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential.

Deaglio S, Vaisitti T, Aydin S, Bergui L, D'Arena G, Bonello L, Omedé P, Scatolini M, Jaksic O, Chiorino G, Efremov D, Malavasi F.

Blood. 2007 Dec 1;110(12):4012-21. Epub 2007 Aug 15.

33.

Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia.

D'Arena G, Tarnani M, Rumi C, Vaisitti T, Aydin S, De Filippi R, Perrone F, Pinto A, Chiusolo P, Deaglio S, Malavasi F, Laurenti L.

Am J Hematol. 2007 Sep;82(9):787-91.

34.

CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity.

Malavasi F, Deaglio S, Ferrero E, Funaro A, Sancho J, Ausiello CM, Ortolan E, Vaisitti T, Zubiaur M, Fedele G, Aydin S, Tibaldi EV, Durelli I, Lusso R, Cozno F, Horenstein AL.

Mol Med. 2006 Nov-Dec;12(11-12):334-41. Review.

35.

CD38/CD19: a lipid raft-dependent signaling complex in human B cells.

Deaglio S, Vaisitti T, Billington R, Bergui L, Omede' P, Genazzani AA, Malavasi F.

Blood. 2007 Jun 15;109(12):5390-8. Epub 2007 Feb 27.

36.
37.

Cationization of monoclonal antibodies: another step towards the "magic bullet"?

Vaisitti T, Deaglio S, Malavasi F.

J Biol Regul Homeost Agents. 2005 Jul-Dec;19(3-4):105-12. Review.

PMID:
16602624
38.

CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells.

Frasca L, Fedele G, Deaglio S, Capuano C, Palazzo R, Vaisitti T, Malavasi F, Ausiello CM.

Blood. 2006 Mar 15;107(6):2392-9. Epub 2005 Nov 17.

39.

CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival.

Deaglio S, Vaisitti T, Bergui L, Bonello L, Horenstein AL, Tamagnone L, Boumsell L, Malavasi F.

Blood. 2005 Apr 15;105(8):3042-50. Epub 2004 Dec 21.

Supplemental Content

Loading ...
Support Center